BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+7.78%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$7.01B
AUM Growth
+$7.01B
(+1.7%)
Cap. Flow
-$225M
Cap. Flow
% of AUM
-3.21%
Top 10 Holdings %
Top 10 Hldgs %
36.63%
Holding
168
New
9
Increased
52
Reduced
52
Closed
12
Top Buys
| 1 |
Eli Lilly
LLY
|
$39.6M |
| 2 |
Evolent Health
EVH
|
$38.1M |
| 3 |
Merck
MRK
|
$34.6M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$27.1M |
| 5 |
Humana
HUM
|
$26.3M |
Top Sells
| 1 |
Apellis Pharmaceuticals
APLS
|
$53.8M |
| 2 |
Sarepta Therapeutics
SRPT
|
$51.1M |
| 3 |
HCA Healthcare
HCA
|
$43.5M |
| 4 |
Intuitive Surgical
ISRG
|
$43.3M |
| 5 |
Boston Scientific
BSX
|
$42.1M |
Sector Composition
| 1 | Healthcare | 99.05% |
| 2 | Industrials | 0.87% |
| 3 | Energy | 0.03% |
| 4 | Communication Services | 0.01% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Elevance Health
ELV
$72.4B
| $45.5M | 0.65% |
102,453
+9,483
| +10% | +$4.21M |
|
|
52
Eli Lilly
LLY
$661B
| $44.6M | 0.64% |
95,155
+84,391
| +784% | +$39.6M |
|
53
Danaher
DHR
$143B
| $44.1M | 0.63% |
183,709
-153,682
| -46% | -$36.9M |
|
|
SILK
54
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $44.1M | 0.63% |
1,356,763
+287,024
| +27% | +$9.33M |
|
55
Zimmer Biomet
ZBH
$20.8B
| $41.5M | 0.59% |
284,835
+19,565
| +7% | +$2.85M |
|
56
Axsome Therapeutics
AXSM
$6.09B
| $41.3M | 0.59% |
574,363
+133,013
| +30% | +$9.56M |
|
57
Black Diamond Therapeutics
BDTX
$164M
| $41.1M | 0.59% |
8,135,839
+2,740,000
| +51% | +$13.8M |
|
58
Globus Medical
GMED
$7.94B
| $38.6M | 0.55% |
647,645
| – | – |
|
59
AtriCure
ATRC
$1.73B
| $37M | 0.53% |
748,613
+101,391
| +16% | +$5M |
|
60
IQVIA
IQV
$31.4B
| $36.4M | 0.52% |
162,120
-10,358
| -6% | -$2.33M |
|
61
Jazz Pharmaceuticals
JAZZ
$7.99B
| $35.8M | 0.51% |
288,779
-281,078
| -49% | -$34.8M |
|
|
62
Merck
MRK
$210B
| $35.4M | 0.5% |
306,694
+299,619
| +4,235% | +$34.6M |
|
63
Cooper Companies
COO
$13.3B
| $33.2M | 0.47% |
86,567
+5,254
| +6% | +$2.01M |
|
64
CareDx
CDNA
$678M
| $31.6M | 0.45% |
3,716,477
+277,386
| +8% | +$2.36M |
|
|
65
BioMarin Pharmaceuticals
BMRN
$11.3B
| $31.3M | 0.45% |
360,604
+312,159
| +644% | +$27.1M |
|
66
Privia Health
PRVA
$2.84B
| $29.3M | 0.42% |
1,122,644
+120,000
| +12% | +$3.13M |
|
67
Procept Biorobotics
PRCT
$2.11B
| $26.2M | 0.37% |
741,517
| – | – |
|
68
Hologic
HOLX
$14.7B
| $23.5M | 0.34% |
290,136
| – | – |
|
69
Fate Therapeutics
FATE
$115M
| $23.1M | 0.33% |
4,855,779
| – | – |
|
|
70
Sarepta Therapeutics
SRPT
$1.98B
| $22.9M | 0.33% |
200,220
-446,394
| -69% | -$51.1M |
|
71
Beam Therapeutics
BEAM
$1.9B
| $22.2M | 0.32% |
695,421
| – | – |
|
72
HUTCHMED
HCM
$2.62B
| $21.7M | 0.31% |
1,805,583
-21,387
| -1% | -$257K |
|
73
Omnicell
OMCL
$1.51B
| $21.6M | 0.31% |
293,345
-170,022
| -37% | -$12.5M |
|
74
ResMed
RMD
$39.4B
| $21.5M | 0.31% |
98,275
| – | – |
|
|
AMED
75
DELISTED
Amedisys
AMED
| $21.4M | 0.31% |
234,318
-308,298
| -57% | -$28.2M |
|